The United States Trotting Association has proposed modifications of the regulatory policy concerning clenbuterol and betamethasone in Standardbred races.
The ARCI Scientific Advisory Group assessed this proposal and reported to the Drug Testing Standards and Practices Committee in April. They reported that in certain circumstances different policies might be appropriate for different types of racing and opened the door to a 96-hour withdrawal time for clenbuterol. They could not, however, support the proposed threshold and will work to determine what an appropriate threshold recommendation might be for a 96-hour withdrawal. The Science Advisory Group also requires further data to assess the betamethasone threshold
The Scientific Advisory Group is expected to meet via conference call in June and any recommendations will be considered by the DTSP Committee prior to the Model Rules meeting in August. This is expected to be an agenda item.
USTA Letter to Commissions with Proposal: 2018 12 03 USTA Medication Letter to Commissions
ARCI Letter to Commissions: 2018 12 10 ARCI LETTER TO COMMISSIONS
USTA Response to ARCI Letter: 2018 12 18 MedCollaborative Response to RCI Letter
RMTC Scientific Advisory Committee Comments on Proposals. 2019 02 13 – RMTC Comments on USTA Medication Proposal. List of Members of the RMTC SAC 2019 RMTC SAC Members
MATERIALS FOR REVIEW:
USTA JUSTIFICATION FOR BREED SPECIFIC POLICY DIFFERENCES FOR THERAPEUTIC MEDICATIONS.
2015 Finding of the NY Gaming Commission – 2019 02 21 NYSGC findings on clenbuterol